

Express Mail No. <u>EV 622 502 632 US</u> Docket No. <u>3828-4000US1</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gelber

Confirmation No.

9860

Serial No.:

09/995,522

Group Art Unit:

1642

Filed:

November 28, 2001

Examiner:

L. Helms

For:

Myeloma Cell And Ovarian Cancer Cell Surface

Glycoprotein, Antibodies Thereto, and Uses Thereof

ISSUE FEE TRANSMITTAL

Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicant hereby submits Form PTOL-85 Part B. The Commissioner is hereby authorized to charge any fees required in connection with this submission to Deposit Account No. 13-4500, Order No. 3828-4000US1. A copy of this sheet is enclosed.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: November 9, 2005

Melissa B. Wenk

Registration No. 53,759

Correspondence Address:

Morgan & Finnegan, L.L.P. 3 World Financial Center New York, New York 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile

27123

↑CUSTOMER NUMBER↑

11-14-05

PART B - FEE(S) TRANSMITTAL

Complete and semb this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

10				<u>Fax (5/1) 2/3-2005</u>			
ins receipt of the appropriate All further corrected by maintenance fee notification.	m should be used for trans respondence including the F elow or directed otherwise s.	mitting the ISSU atent, advance of in Block 1, by (a	JE FEE and rders and not a) specifying	PUBLICATION FEE (if requification of maintenance fees a new correspondence address	uired). Blocks I through 5 sl will be mailed to the current s; and/or (b) indicating a sepa	hould be completed wh correspondence address trate "FEE ADDRESS"	
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block I for any change of address)				Note: A certificate o	Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, mutually the such as a such		
75	90 08/10/2005			have its own certifica	te of mailing or transmission.	in or formal drawing, in	
MORGAN & FIN	NEGAN, L.L.P.			Ce	ertificate of Mailing or Trans	m IssIon	
345 Park Avenue New York, NY 10154-0053				I hereby certify that t States Postal Service	I hereby certify that this Fee(s) Transmittal is being deposited with the Unit States Postal Service with sufficient postage for first class mail in an enveloy addressed to the Mail Stop ISSUE FEE address above, or being facsimi transmitted to the USPTO (571) 273-2885, on the date indicated below.		
				addressed to the Ma transmitted to the US			
15/2005 MAHMED2 000000	60 134500 09995522					(Depositor's name	
FC:2501 700.00 DA						(Signatu	
C:1504 300.00 D FC:8001 6.00			.			(Da	
APPLICATION NO.	FILING DATE	FIRS		D INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/995,522 TITLE OF INVENTION: M	11/28/2001 YELOMA CELL AND OV	ARIAN CANCER		a Gelber FACE GLYCOPROTEINS, AN	3828-4000US1 VTIBODIES THERETO, AND	9860 OUSES THEREOF	
APPLN. TYPE	SMALL ENTITY	ISSUE FEE		PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	nonprovisional YES			\$300	\$1000	11/10/2005	
EXAMINER		ART UN	IIT	CLASS-SUBCL ASS	7	•	
YAO, LEI		1642		424-133100	J		
1. Change of correspondence	address or indication of "Fe	e Address" (37	2. For pri	nting on the patent front page, I	ist Morgan	& Finnega	
CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.			(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,				
							"Fee Address" indicati PTO/SB/47; Rev 03-02 of Number is required.
3. ASSIGNEE NAME AND	RESIDENCE DATA TO BI	PRINTED ON T	HE PATEN	Γ (print or type)			
PLEASE NOTE: Unless recordation as set forth in	an assignee is identified bel 37 CFR 3.11. Completion o	ow, no assignee f this form is NO	data will app F a substitute	pear on the patent. If an assign for filing an assignment.	nee is identified below, the do	ocument has been filed	
(A) NAME OF ASSIGNE	Ε	(B) RESIDEN	CE: (CITY and STATE OR CO	UNTRY)		
Molecular Di	L.I.C.	New York, New York					
Please check the appropriate	assignee category or categor	es (will not be pr	inted on the p	patent): 🗖 Individual 🛱 C	Corporation or other private gro	up entity 🚨 Governme	
4a. The following fee(s) are e	nclosed:	, 4b	p. Payment of Fee(s):				
Issue Fee		A check in the amount of the fee(s) is enclosed.					
Publication Fee (No small entity discount permitted) Advance Order - # of Copies			Payment by credit card. Form PTO-2038 is attached.				
			The Director is hereby authorized by charge the required fee(s), or credit any overpayment, Deposit Account Number				
5. Change In Entity Status (a. Applicant claims SM	from status indicated above) 1ALL ENTITY status. See 3		b. Applic	ant is no longer claiming SMA	LL ENTITY status. See 37 CF	FR 1.27(g)(2).	
The Director of the USPTO is NOTE: The Issue Fee and Pu interest as shown by the record	s requested to apply the Issue blication Fee (if required) w ds of the United States Pater	Fee and Publicate Fee and Publicate I not be accepted at and Trademark	tion Fee (if ar I from anyone Office.	ny) or to re-apply any previous e other than the applicant; a reg	ly paid issue fee to the applicat istered attorney or agent; or the	ion identified above. e assignee or other party	
Authorized Signature	Metons	link		Date	November 9,	2005	
Typed or printed name	<u>Melissa B.</u>				No. <u>53,759</u>		
This collection of information an application. Confidentialit submitting the completed app this form and/or suggestions Box 1450. Alexandria. Virgin	n is required by 37 CFR 1.31 y is governed by 35 U.S.C. olication form to the USPTC for reducing this burden, sho nia 22313-1450. DO NOT S	1. The information 122 and 37 CFR 12. Time will vary buld be sent to the FND FEES OR (n is required 1.14. This col depending u Chief Infort COMPLETED	to obtain or retain a benefit by lection is estimated to take 12 pon the individual case. Any con nation Officer, U.S. Patent and D FORMS TO THIS ADDRES	the public which is to file (and minutes to complete, including omments on the amount of tin Trademark Office, U.S. Depa S. SEND TO: Commissioner for	by the USPTO to process g gathering, preparing, and you require to complet rtment of Commerce, P. 6	

Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gelber

Confirmation No.

9860

Serial No.:

09/995,522

Group Art Unit:

1642

Filed:

November 28, 2001

Examiner:

L. Helms

For:

Myeloma Cell And Ovarian Cancer Cell Surface Glycoprotein, Antibodies Thereto, and Uses Thereof

EXPRESS MAIL CERTIFICATE

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

I hereby certify that the following attached papers and fee

- 1. Issue Fee Transmittal (w/ duplicate)
- 2. Form PTOL-85 Part B (w/ duplicate)
- 3. Return receipt postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on November 9, 2005 and is addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Melissa Wenk

(Typed or printed name of person mailing papers and fee)

(Signature of person mailing papers and fee)

Correspondence Address:

Morgan & Finnegan, L.L.P. 3 World Financial Center New York, New York 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile